We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Drug–Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection.
- Authors
Marzolini, Catia; Gibbons, Sara; van Oosterhout, Joep J.; Khoo, Saye
- Abstract
Drug-drug interactions were graded into four levels: red flags for contraindicated drug associations that may have deleterious consequences; amber for potential clinically relevant interactions manageable by close monitoring or dosage adjustment; yellow for interactions of weak intensity with no need for additional monitoring or dosage adjustment; and green for no clinically significant interaction expected. Table 2 provides the drug-drug interaction potential as well as dosing and monitoring recommendations for selected comedications. With the exception of vinblastine (inhibitor of arylacetamide deacetylase [[17]]) and paracetamol (inhibitor of arylacetamide deacetylase [[18]]), few drugs were shown to inhibit these enzymes and therefore rifapentine and isoniazid have a low potential to be impacted by other drugs. Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection.
- Subjects
LATENT tuberculosis; RIFAMPIN; EFAVIRENZ; DRUG interactions; ISONIAZID; POLYPHARMACY; CYTOCHROME P-450 CYP3A
- Publication
Clinical Pharmacokinetics, 2022, Vol 61, Issue 3, p339
- ISSN
0312-5963
- Publication type
Article
- DOI
10.1007/s40262-021-01098-8